Beyond Celiac is actively funding the most promising research to help speed up the development of treatments for patients. We have also partnered with a number of pharmaceutical companies to accelerate clinical trials through patient recruitment and education.
Strategic partnerships are a key part of our Science Plan aimed at realizing an effective treatment or cure for celiac disease by 2030. Our partnerships advance scientific priorities, aid in overcoming challenges, and maximize progress toward our shared goals. Partner with Beyond Celiac today to learn more about our strategic science partnerships. Contact Mary Kate Carofano at [email protected] today.
Since 2016, Beyond Celiac has been involved with assisting a number of clinical studies in all phases. With the largest celiac disease social community, a robust email and research database and a website that receives over 2 million visits a year, we are uniquely qualified to help your clinical trial recruit qualified candidates.
Reach and resonate with qualified candidates
...and more. Read more about all our clinical trial services.
There are multiple pathways on the horizon for drug research, discovery and development. We know that the first need in achieving a cure for celiac disease is adequate funding. The second, related need is equally important: we need to maintain our focus on research that is practical and patient-centric. We have designed our scientific plan accordingly. Our research funding is directed in two primary ways, innovative grants and established investigator awards. Learn more about our grant program.
We believe that with a strategic approach to research,
an effective treatment or cure is possible by 2030.
Go Beyond Celiac is an online patient registry and app that collects data to accelerate research for celiac disease. Share your experiences to help change the future for those living with this serious autoimmune disease.
If you're a researcher interested in accessing patient data from Go Beyond Celiac or working with us on a survey, contact our platform coordinator at [email protected].
Opt-in to stay up-to-date on the latest news.
Yes, I want to advance research No, I'd prefer not to